drugset / Trial / NCT00674661

Corneal Collagen Cross-Linking for Ectasia (CXL)

NCT00674661

Phase 3 Completed 130 enrolled Glaukos Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.

Timeline

Start
2007-12
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Riboflavin Other / unclassified 0.1 %
Comparator Riboflavin Other / unclassified 1.6 ml

Indications